<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Clinical manifestations and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sorin Pislaru, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Heidi M Connolly, MD, FACC, FASE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Theo E Meyer, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 29, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H121889226"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Replacement of a diseased heart valve with a prosthetic heart valve exchanges the native disease for prosthesis-related complications [<a href="#rid1">1-3</a>]. Complications include prosthetic valve obstruction (including prosthetic valve thrombosis [PVT] and pannus formation), embolic events, bleeding, prosthetic valve regurgitation (valvular and paravalvular), infective endocarditis, and prosthetic valve-related hemolysis. (See  <a class="medical medical_review" href="/z/d/html/8134.html" rel="external">"Overview of the management of patients with prosthetic heart valves"</a>.)</p><p>This topic discusses the clinical manifestations and diagnosis of surgical or transcatheter bioprosthetic valve thrombosis (BPVT), thromboembolism, and obstruction.</p><p>Related issues are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Risk of thrombotic complications (thromboembolism and valve thrombosis) of surgical and transcatheter bioprosthetic valves. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair", section on 'Risk of thrombotic complications with a surgical bioprosthetic valve'</a> and  <a class="medical medical_review" href="/z/d/html/110074.html" rel="external">"Transcatheter aortic valve implantation: Complications", section on 'Valve thrombosis'</a> and  <a class="medical medical_review" href="/z/d/html/131939.html" rel="external">"Transcatheter aortic valve implantation: Antithrombotic therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antithrombotic therapy to reduce the risk of thrombotic bioprosthetic valve complications. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair"</a> and  <a class="medical medical_review" href="/z/d/html/131939.html" rel="external">"Transcatheter aortic valve implantation: Antithrombotic therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of bioprosthetic obstruction, thromboembolism, and thrombosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who are not pregnant. (See  <a class="medical medical_review" href="/z/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who are pregnant. (See  <a class="medical medical_review" href="/z/d/html/113664.html" rel="external">"Management of risks of prosthetic valves during pregnancy", section on 'Risks associated with prosthetic valves'</a>.)</p><p></p><p class="headingAnchor" id="H2099675841"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>PVT and valve obstruction are partially overlapping conditions.</p><p class="headingAnchor" id="H2723781111"><span class="h2">Thrombotic complications</span><span class="headingEndMark"> — </span>Thrombus forming on a bioprosthetic valve can cause thromboembolism and/or BPVT. BPVT can be nonobstructive or obstructive and may or may not be associated with clinical thromboembolic events [<a href="#rid4">4-7</a>],. The incidence of these complications is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair", section on 'Risk of thrombotic complications with a surgical bioprosthetic valve'</a>.)</p><p class="headingAnchor" id="H3476006697"><span class="h2">Valve dysfunction</span><span class="headingEndMark"> — </span>Bioprosthetic valve dysfunction includes valve obstruction, regurgitation, and mixed stenosis and regurgitation. These conditions can occur days to years after valve replacement. Causes of bioprosthetic valve dysfunction include structural degeneration/pannus formation (which may be accompanied by calcification), thrombosis [<a href="#rid8">8</a>], and rarely, infective endocarditis [<a href="#rid9">9</a>]. These causes can occur concurrently (eg, concurrent thrombus and pannus or concurrent thrombus and endocarditis) [<a href="#rid9">9</a>]. Pannus formation is caused by fibrous tissue ingrowth around the prosthetic valve. The incidence of bioprosthetic valve dysfunction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement", section on 'Valve durability'</a> and  <a class="medical medical_review" href="/z/d/html/110074.html" rel="external">"Transcatheter aortic valve implantation: Complications", section on 'Longer-term complications'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstruction</strong> – Normally functioning bioprosthetic valves are intrinsically obstructive compared with normal native valves. Prosthetic valve obstruction is defined as an impairment to flow above and beyond that usually seen under baseline hemodynamic conditions for the specific bioprosthetic valve type and size. This usually manifests as an increase in the transvalvular pressure gradient and a decrease in effective prosthetic orifice area compared to baseline ("fingerprint" data obtained immediately postimplantation).</p><p></p><p class="bulletIndent1">Pannus is a more common cause of bioprosthetic valve obstruction than thrombosis, but the two causes often present similarly. Some studies suggest that BPVT has been an underrecognized cause of valve obstruction, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/132746.html" rel="external">"Antithrombotic therapy for surgical bioprosthetic valves and surgical valve repair", section on 'Bioprosthetic valve thrombosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regurgitation</strong> – Bioprosthetic valve regurgitation is most commonly caused by structural degeneration, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/111634.html" rel="external">"Clinical manifestations and diagnosis of surgical aortic and mitral prosthetic valve regurgitation"</a>.)</p><p></p><p>The valve dysfunction caused by BPVT is predominantly obstruction (stenosis), sometimes mixed obstruction and regurgitation, and, least frequently, isolated regurgitation (respectively 54, 33, and 11 percent in one series [<a href="#rid10">10</a>]). (See  <a class="medical medical_review" href="/z/d/html/111634.html" rel="external">"Clinical manifestations and diagnosis of surgical aortic and mitral prosthetic valve regurgitation"</a>.)</p><p class="headingAnchor" id="H2287612781"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H753787424"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Clinical manifestations in patients with bioprosthetic valve obstruction range from an incidentally detected change in valve appearance or valve gradient observed on an echocardiogram performed for other reasons, thromboembolism, symptoms and signs of heart failure (HF) caused by valve dysfunction (eg, dyspnea, fatigue, rales, cardiogenic shock), presyncope or syncope, and, rarely, sudden death [<a href="#rid11">11</a>].</p><p>Symptoms and signs of a thromboembolic event may occur with or without concurrent valve obstruction. Left-sided PVT (mitral or aortic) may cause systemic embolic events such as stroke or, rarely, myocardial infarction [<a href="#rid12">12,13</a>]. Right-sided (tricuspid or pulmonic) PVT may cause pulmonary emboli; tricuspid PVT can also cause systemic emboli via paradoxical embolization.</p><p class="headingAnchor" id="H696744709"><span class="h2">Initial tests</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests</strong> – Initial laboratory tests include a complete blood count, an international normalized ratio (INR) in patients who have been treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and an electrocardiogram (ECG) in patients presenting with HF or signs of an acute coronary syndrome.</p><p></p><p class="bulletIndent1">If the hemoglobin level is low, evaluation of anemia should include a hemolysis work-up (assessment of the peripheral smear, reticulocyte count, and serum lactate dehydrogenase (LDH), bilirubin, free hemoglobin, and haptoglobin levels), as discussed separately. Bioprosthetic valve obstruction or regurgitation is sometimes associated with hemolysis. (See  <a class="medical medical_review" href="/z/d/html/8134.html" rel="external">"Overview of the management of patients with prosthetic heart valves", section on 'Hemolytic anemia'</a> and  <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'Laboratory confirmation of hemolysis'</a>.)</p><p></p><p class="bulletIndent1">Additional testing for patients with suspected HF, including assessment of natriuretic peptide levels (B-type natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP]) [<a href="#rid14">14</a>], is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram</strong> – An ECG is indicated in patients presenting with symptoms suggestive of HF (eg, dyspnea, edema), an acute coronary syndrome (eg, chest pain), or stroke. The ECG is generally nondiagnostic in patients with BPVT or thromboembolism. However, the ECG may help identify other causes of symptoms such as an acute coronary syndrome or arrhythmia (eg, atrial fibrillation). As noted above, coronary thromboembolism from a prosthetic valve is a rare cause of myocardial infarction. (See  <a class="medical medical_review" href="/z/d/html/184.html" rel="external">"Initial evaluation and management of suspected acute coronary syndrome (myocardial infarction, unstable angina) in the emergency department", section on 'Electrocardiogram assessment'</a> and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults", section on 'Initial testing'</a> and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke", section on 'Initial assessment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Echocardiogram</strong> – The key role of echocardiography in the diagnosis and evaluation of BPVT or obstruction is discussed below. (See <a class="local">'Initial echocardiography'</a> below.)</p><p></p><p class="headingAnchor" id="H3800172701"><span class="h1">INITIAL EVALUATION</span><span class="headingEndMark"> — </span>Our approach to evaluating patients with suspected BPVT and/or bioprosthetic valve obstruction includes an initial clinical evaluation (including transthoracic echocardiogram [TTE]), further evaluation (including three-dimensional [3D] transesophageal echocardiography [TEE] and/or four-dimensional [4D] computed tomography [CT]), and application of diagnostic criteria.</p><p class="headingAnchor" id="H3283746374"><span class="h2">When to suspect BPVT or obstruction</span><span class="headingEndMark"> — </span>BPVT and/or obstruction should be suspected in a patient with a prosthetic valve with a new or changed murmur or symptoms and signs of HF (eg, dyspnea, fatigue, pulmonary crackles, syncope, cardiogenic shock). In some patients, the first sign of PVT or obstruction is an incidentally detected change in valve appearance (restricted leaflet motion with leaflet thickening or mass) and/or increased valve gradient observed on echocardiography (see <a class="local">'Symptoms and signs'</a> above). Of note, European Society of Cardiology (ESC) and American College of Cardiology/American Heart Association (ACC/AHA) guidelines on valvular heart disease differ in their recommendations on echocardiographic surveillance. The ESC guideline recommends yearly echocardiography for all bioprostheses [<a href="#rid3">3</a>], whereas the ACC/AHA guideline recommends yearly echocardiographic evaluation for TAVR, but only at five years or symptom change for surgical bioprostheses [<a href="#rid2">2</a>].</p><p>Prosthetic valve thromboembolism should be suspected in a patient with a prosthetic valve presenting with a stroke or other thromboembolic event. However, since thromboembolism in a patient with a prosthetic valve may or may not originate from the prosthesis, other causes should also be evaluated, as described below.</p><p class="headingAnchor" id="H329267652"><span class="h2">Initial echocardiography</span><span class="headingEndMark"> — </span>As an initial step in evaluating patients with suspected PVT, obstruction, or thromboembolism, we suggest imaging by TTE:</p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive TTE evaluation should start with a meticulous inspection of the bioprosthetic valve appearance. This step is frequently overlooked, but strongly endorsed by the American Society of Echocardiography [<a href="#rid15">15</a>] and European Association of Cardiovascular Imaging [<a href="#rid16">16</a>]. Abnormal cusp thickness and mobility (<a class="graphic graphic_movie graphicRef109536" href="/z/d/graphic/109536.html" rel="external">movie 1</a> and <a class="graphic graphic_movie graphicRef109537" href="/z/d/graphic/109537.html" rel="external">movie 2</a>) and presence of regurgitation (prosthetic or periprosthetic) provide important clues of prosthetic dysfunction, although TTE views may be limited. (See  <a class="medical medical_review" href="/z/d/html/5333.html" rel="external">"Echocardiographic evaluation of prosthetic heart valves"</a>.)</p><p></p><p class="bulletIndent1">The TTE study is compared with the baseline ("fingerprint") TTE that is routinely obtained in all patients after implantation of a surgical or transcatheter valve. If fingerprint TTE data are not available, comparison should be performed with published data on normal range, included in imaging guidelines [<a href="#rid15">15</a>] and/or available from the manufacturer website. (See  <a class="medical medical_review" href="/z/d/html/8134.html" rel="external">"Overview of the management of patients with prosthetic heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/108265.html" rel="external">"Transcatheter aortic valve implantation: Periprocedural and postprocedural management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second step is measurement of the prosthetic mean transvalvular pressure gradient and calculation of effective orifice area (see <a class="local">'Diagnosis of obstruction'</a> below). Significant changes compared to baseline are highly suggestive of prosthetic dysfunction. However, immobilization of a single cusp does not necessarily result in a change in transvalvular gradients [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The final step in TTE evaluation is an assessment of left and right ventricular function, which will provide hemodynamic context to compare findings with the "fingerprint" echocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TTE is the preferred initial test for assessment of prosthetic valve function. However, commonly used algorithms have limited ability to correctly identify the cause of high gradients, with an overall accuracy of 57 to 62 percent in a series of 266 patients with a known mechanism of aortic bioprosthetic dysfunction [<a href="#rid18">18</a>]. A novel algorithm combining visual cues with Doppler indexes had an overall accuracy of 83 percent. Similarly, in a study of TTE examinations of 324 mitral bioprostheses (of which 88 were dysfunctional) and 647 mitral mechanical prostheses (138 dysfunctional), a proposed algorithm based on a combination of TTE indexes was incorrect 28 percent of the time when diagnosing obstruction, 33 percent when diagnosing regurgitation, and missed pathologic regurgitation in 8 percent of patients deemed normal [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the limitations of TTE evaluation and associated algorithms, we have a low threshold to recommend advanced imaging with 3D TEE or 4D cardiac CT angiography whenever prosthetic dysfunction is suspected. (See  <a class="medical medical_review" href="/z/d/html/5333.html" rel="external">"Echocardiographic evaluation of prosthetic heart valves"</a>.)</p><p></p><p class="headingAnchor" id="H1846676070"><span class="h2">Diagnosis of obstruction</span><span class="headingEndMark"> — </span>Prosthetic valve obstruction is identified by a mean transvalvular pressure gradient that is &gt;50 percent compared with baseline (or by a mean gradient ≥20 mmHg or an increase in mean gradient ≥10 mmHg for an aortic prosthesis [<a href="#rid20">20</a>]). Other causes of an elevated gradient, such as high flow, patient-prosthesis mismatch, or pressure recovery, should be excluded. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>If a prior postoperative baseline TTE is not available for comparison, a prosthetic valve gradient above established normal values (above the 95% CI) for valves of that type and size (eg, normal values compiled in the 2009 American Society of Echocardiography <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fasecho.org%2Fwp-content%2Fuploads%2F2014%2F05%2F2009_Evaluation-of-Prosthetic-Valves.pdf&amp;token=4BrVyU5mWG5OaPUKU5XpYJcbp53uJLv%2B%2F1mD5iKBe2KiJ1gNPPiXv24lhC9UAoVvLeWfmXxghIEVaQ4QhqhZtOz9A7JQenRAsTs9SxkdUG%2FJQChAYL6ZPNTT8HTJlhxo&amp;TOPIC_ID=113815" target="_blank">guidelines</a> [<a href="#rid15">15</a>] and the 2016 European Association of Cardiovascular Imaging <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fehjcimaging%2Farticle%2F17%2F6%2F589%2F2240571&amp;token=W3fW5rrLv4NkTKucy1j34fwZxzUknwXLW0cYD4i8TNuVQT9ywErmkkK0y0PDU8vvPzEUdLfuIdcQDJayecESjwzbvH2q%2BGrRsxtMfr3tae8%3D&amp;TOPIC_ID=113815" target="_blank">recommendations</a> [<a href="#rid16">16</a>]) is suggestive of prosthetic valve obstruction, although patient-prosthesis mismatch may also be a cause. (See  <a class="medical medical_review" href="/z/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement", section on 'Prosthetic valve-patient mismatch'</a>.)</p><p>Other causes of an elevated gradient, such as a high-output state, should be excluded. (See <a class="local">'Initial evaluation'</a> above and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3281897259"><span class="h1">ADDITIONAL EVALUATION</span></p><p class="headingAnchor" id="H1172681923"><span class="h2">Role of advanced imaging</span><span class="headingEndMark"> — </span>We suggest evaluation with advanced imaging when bioprosthetic valve thrombosis, thromboembolism, and/or obstruction is suspected after initial evaluation and imaging by TTE. </p><p>This evaluation is expedited in patients with bioprosthetic valve obstruction causing moderate or severe symptoms (New York Heart Association [NYHA] functional class III or IV). (See  <a class="medical medical_review" href="/z/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management", section on 'For moderate to severe symptoms of obstruction'</a>.)</p><p>The choice between 3D TEE or 4D CT is made based upon test availability, prior imaging results, patient characteristics, bioprosthetic valve location, and clinician/center experience. In select patients, both imaging modalities are performed for further assessment of the bioprosthetic valve.</p><p>Both 3D TEE and 4D CT enable assessment of bioprosthetic valve leaflet appearance and motion including detection of bioprosthetic leaflet thickening and restricted leaflet motion. While TEE is generally the test of choice for identifying causes of emboli other than BPVT, cardiac CT is also helpful for identifying alternative diagnoses as it can identify vegetations with accuracy approaching that of TEE [<a href="#rid21">21</a>], and cardiac CT with a delayed imaging acquisition protocol can identify atrial thrombi with accuracy nearing that of TEE [<a href="#rid22">22,23</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start with 3D TEE</strong> - 3D TEE is indicated in the following settings, as it may detect prosthetic thrombi and other abnormalities that are not well visualized by TTE or 2D TEE [<a href="#rid24">24</a>] (see  <a class="medical medical_review" href="/z/d/html/5333.html" rel="external">"Echocardiographic evaluation of prosthetic heart valves"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If TTE assessment of bioprosthetic valve function is suboptimal, 3D TEE is preferred as it may be helpful in assessing bioprosthetic valve obstruction (elevated transvalvular gradient) and regurgitation. (See <a class="local">'Diagnosis of obstruction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For bioprosthetic mitral and tricuspid valves, 3D TEE is preferred.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with contraindications to CT (including contraindication to CT contrast), TEE is preferred.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a thromboembolic event (eg, stroke) and/or suspected infective endocarditis, TEE is generally preferred.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to start with 4D CT</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4D CT is preferred for the patient with contraindication to TEE.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4D CT is preferred for a patient known to have suboptimal TEE prosthetic valve images.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>4D CT may be preferred for transcatheter aortic bioprosthetic valves, particularly if prior TEE images are suboptimal. (See  <a class="medical medical_review" href="/z/d/html/86447.html" rel="external">"Imaging for transcatheter aortic valve implantation", section on 'Long-term follow-up'</a>.)</p><p></p><p>If the bioprosthetic valve is not adequately visualized by TEE or 4D CT, we suggest performing the alternate test, if feasible.</p><p class="headingAnchor" id="H3107069073"><span class="h2">Diagnosis of BPVT or pannus</span><span class="headingEndMark"> — </span>The presence of increased cusp thickness with restricted leaflet mobility is suggestive of BPVT or pannus. BPVT is presumptively diagnosed when <strong>both</strong> of the following features are present on TEE and/or 4D CT with characteristics consistent with BPVT:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased cusp thickness</strong> – BPVT appears as diffuse or focal soft echodense cusp thickness &gt;2mm on TEE or hypoattenuated leaflet thickening (HALT) [<a href="#rid25">25</a>] on 4D CT with the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Respects cusp edges</strong> – With BPVT, the valve thickening usually respects the cusp edges. In contrast, pannus usually appears to overlay the valve (<a class="graphic graphic_figure graphicRef129688" href="/z/d/graphic/129688.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef129689" href="/z/d/graphic/129689.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef129690" href="/z/d/graphic/129690.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Downstream</strong> – BPVT is generally located on the downstream side of the bioprosthetic valve (<a class="graphic graphic_figure graphicRef129689" href="/z/d/graphic/129689.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef129690" href="/z/d/graphic/129690.html" rel="external">figure 3</a> and <a class="graphic graphic_movie graphicRef129692" href="/z/d/graphic/129692.html" rel="external">movie 3</a> and <a class="graphic graphic_movie graphicRef129700" href="/z/d/graphic/129700.html" rel="external">movie 4</a>) [<a href="#rid26">26</a>], although mitral BPVT has also been visualized on the upstream side of the valve [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No or mild calcification</strong> – BPVT is usually associated with no more than mild cusp calcification. Greater calcification is usually associated with a degenerated bioprosthetic valve rather than thrombus (<a class="graphic graphic_figure graphicRef129688" href="/z/d/graphic/129688.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef129689" href="/z/d/graphic/129689.html" rel="external">figure 2</a> and <a class="graphic graphic_figure graphicRef129690" href="/z/d/graphic/129690.html" rel="external">figure 3</a>). However, the presence of valve calcification does not rule out a thrombotic component, particularly if other imaging features clearly suggest thrombus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restricted leaflet mobility </strong>–<strong> </strong>Restrictive bioprosthetic leaflet mobility is a key feature of BPVT identified by TTE, TEE, or 4D CT (<a class="graphic graphic_movie graphicRef129692" href="/z/d/graphic/129692.html" rel="external">movie 3</a> and <a class="graphic graphic_movie graphicRef129691" href="/z/d/graphic/129691.html" rel="external">movie 5</a> and <a class="graphic graphic_movie graphicRef129699" href="/z/d/graphic/129699.html" rel="external">movie 6</a> and <a class="graphic graphic_movie graphicRef129700" href="/z/d/graphic/129700.html" rel="external">movie 4</a>), but cusp immobility alone is not diagnostic of BPVT, as cusp immobility is also seen with bioprosthetic valve degeneration and pannus formation (<a class="graphic graphic_movie graphicRef129702" href="/z/d/graphic/129702.html" rel="external">movie 7</a> and <a class="graphic graphic_movie graphicRef129701" href="/z/d/graphic/129701.html" rel="external">movie 8</a> and <a class="graphic graphic_movie graphicRef129698" href="/z/d/graphic/129698.html" rel="external">movie 9</a> and <a class="graphic graphic_movie graphicRef129696" href="/z/d/graphic/129696.html" rel="external">movie 10</a>) [<a href="#rid28">28</a>]. Furthermore, abnormal cusp mobility can be detected by intraoperative TEE of apparently normal bioprostheses, possibly due to focal hemodynamic milieu [<a href="#rid29">29</a>].</p><p></p><p>BPVT should be distinguished from other causes of prosthetic cusp thickening, such as endocarditis. The diagnosis of BPVT may be confirmed by resolution of prosthetic valve thickening/mass with anticoagulation or pathologic inspection after prosthesis removal. (See  <a class="medical medical_review" href="/z/d/html/111633.html" rel="external">"Bioprosthetic valve thrombosis, thromboembolism, and obstruction: Management", section on 'Antithrombotic therapy'</a>.)</p><p>Limited data are available on distinguishing bioprosthetic valve thrombus and pannus on echocardiography. Echocardiographic diagnostic criteria (greater than 50 percent increase in mean prosthetic valve gradient from baseline within five years, increased cusp thickness, and impaired cusp mobility) were developed based upon a retrospective study of 32 patients with BPVT [<a href="#rid30">30</a>] and confirmed in a prospective study of 52 patients with suspected BPVT followed for a mean of 85 weeks [<a href="#rid31">31</a>]. Presence of all three criteria predicted a positive response (≥50 percent reduction in mean valve gradient) to vitamin K antagonist therapy with a sensitivity of 88 percent, specificity of 93 percent, positive predictive value of 91 percent, and negative predictive value of 85 percent [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H3899450972"><span class="h2">Diagnosis of thromboembolism</span><span class="headingEndMark"> — </span>When a patient with a bioprosthetic valve experiences a presumed thromboembolic event (eg stroke), a diagnosis of thromboembolism from the bioprosthetic valve is made after excluding other causes of stroke and embolic events. In patients with bioprosthetic valve thromboembolism, thrombus may or may not be visualized on the bioprosthetic valve. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a> and <a class="local">'For valve thromboembolism or thrombosis'</a> below.)</p><p class="headingAnchor" id="H1607310824"><span class="h2">Evaluate thrombophilia</span><span class="headingEndMark"> — </span>Patients with bioprosthetic valves who develop BPVT or thromboembolism should undergo evaluation for an inherited thrombophilia. The most concerning inherited thrombophilias are those associated with a personal or strong family history of thrombosis, including antithrombin (AT) deficiency and homozygosity or compound heterozygosity for the factor V Leiden and/or prothrombin G20210A. (See  <a class="medical medical_review" href="/z/d/html/1364.html" rel="external">"Screening for inherited thrombophilia in asymptomatic adults"</a> and  <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">"Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors"</a>.)</p><p class="headingAnchor" id="H408347518"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H1719000741"><span class="h2">For valve obstruction</span><span class="headingEndMark"> — </span>Valve obstruction should be distinguished from other causes of left ventricular outflow tract (LVOT) obstruction or increased prosthetic transvalvular pressure gradients, such as patient-prosthesis mismatch, prosthetic valve regurgitation, endocarditis, and increased stroke volume (eg, due to high-output state).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient-prosthesis mismatch</strong> – Comparison with a baseline postoperative TTE and patient characteristics is helpful in distinguishing a new valve obstruction from patient-prosthesis mismatch (with which the transvalvular gradient would be similarly elevated in postoperative studies assuming body habitus has not changed). (See  <a class="medical medical_review" href="/z/d/html/8143.html" rel="external">"Choice of prosthetic heart valve for surgical aortic or mitral valve replacement", section on 'Prosthetic valve-patient mismatch'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regurgitation</strong> – Bioprosthetic valve regurgitation (transvalvular or paravalvular) should be excluded by TTE and/or TEE. TEE is particularly helpful for diagnosis of prosthetic/periprosthetic mitral or tricuspid regurgitation. Bioprosthetic valve regurgitation is most commonly caused by structural degeneration. BPVT is a less common cause. Transvalvular prosthetic valve regurgitation should be distinguished from paravalvular regurgitation. (See  <a class="medical medical_review" href="/z/d/html/111634.html" rel="external">"Clinical manifestations and diagnosis of surgical aortic and mitral prosthetic valve regurgitation"</a> and  <a class="medical medical_review" href="/z/d/html/5333.html" rel="external">"Echocardiographic evaluation of prosthetic heart valves", section on 'Prosthetic valve regurgitation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased stroke volume</strong> – A clinical history suggestive of a high-output state (such as sepsis or severe anemia [<a href="#rid32">32</a>]) as well as echocardiographic evidence of hyperdynamic left ventricular systolic function and elevated LVOT velocities are suggestive of increased stroke volume as a cause of transiently increased transvalvular gradients. (See  <a class="medical medical_review" href="/z/d/html/3462.html" rel="external">"Causes and pathophysiology of high-output heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular outflow tract obstruction</strong> – For patients with suspected prosthetic aortic valve obstruction, imaging (primarily by TTE) is also helpful in identifying alternate causes of LVOT obstruction, including interventricular septal hypertrophy and protruding mitral prosthesis. (See  <a class="medical medical_review" href="/z/d/html/5333.html" rel="external">"Echocardiographic evaluation of prosthetic heart valves", section on 'Prosthetic aortic stenosis'</a>.)</p><p></p><p>In patients with prosthetic valve obstruction and symptoms and signs of HF, alternate or concomitant causes of these findings (such as left ventricular systolic and/or diastolic dysfunction, respiratory disorders, or deconditioning) should be evaluated. (See  <a class="medical medical_review" href="/z/d/html/1436.html" rel="external">"Approach to the patient with dyspnea"</a> and  <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H3271337419"><span class="h2">For valve thromboembolism or thrombosis</span><span class="headingEndMark"> — </span>The differential diagnosis of thromboembolism or stroke from a prosthetic valve includes other cardiogenic and noncardiogenic sources [<a href="#rid33">33</a>]. Patients with a prosthetic valve who have a stroke or other thromboembolic event should undergo a comprehensive cardiovascular and neurologic evaluation including an ECG, monitoring for occult atrial fibrillation, brain imaging, and vascular imaging. The diagnosis and evaluation of embolic stroke and other embolic events are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1134.html" rel="external">"Clinical diagnosis of stroke subtypes"</a> and  <a class="medical medical_review" href="/z/d/html/8213.html" rel="external">"Clinical features and diagnosis of acute lower extremity ischemia"</a> and  <a class="medical medical_review" href="/z/d/html/96754.html" rel="external">"Acute mesenteric arterial occlusion"</a>.)</p><p>BPVT should be distinguished from other causes of prosthetic cusp thickening and impaired valve leaflet mobility, including prosthetic valve endocarditis (PVE). While PVE generally presents with signs and symptoms of invasive infection, it occasionally has an occult presentation and is detected by test findings (eg, presence of vegetation and positive blood cultures). If a diagnosis of PVE is uncertain, follow-up testing (ie, repeat TEE, CT, positron emission tomography, and other testing for PVE) is recommended to determine whether or not PVE is present. Clinical manifestations, diagnosis, and management of PVE are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2138.html" rel="external">"Prosthetic valve endocarditis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">"Antimicrobial therapy of prosthetic valve endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/2132.html" rel="external">"Surgery for prosthetic valve endocarditis"</a>.)</p><p class="headingAnchor" id="H2531363260"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/115482.html" rel="external">"Society guideline links: Cardiac valve disease"</a>.)</p><p class="headingAnchor" id="H3558808427"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioprosthetic valve thrombosis and valve obstruction</strong> – These are partially overlapping conditions. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic complications of bioprosthetic valves</strong> – Thrombus forming on a bioprosthetic valve can cause thromboembolism and/or bioprosthetic valve thrombosis (BPVT). BPVT may be subclinical or cause symptomatic valve dysfunction. The valve dysfunction caused by BPVT is predominantly obstruction (stenosis), sometimes mixed obstruction and regurgitation, and, least frequently, isolated regurgitation. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bioprosthetic valve obstruction</strong> – Causes of bioprosthetic valve obstruction include structural degeneration/pannus formation, thrombosis, and, rarely, infective endocarditis. These causes can occur separately or concurrently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Thrombus on a bioprosthetic valve can result in symptoms and signs of thromboembolism and/or valve thrombosis with valve dysfunction (obstruction and/or regurgitation). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incidental finding</strong> – Evidence of valve thrombosis or obstruction may be identified by cardiac imaging (eg, echocardiography) in a patient with no symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thromboembolic manifestations</strong> – Symptoms and signs of thromboembolism vary with the location of the prosthetic valve. Left-sided (mitral or aortic) BPVT can cause systemic embolic events such as stroke or, rarely, myocardial infarction. Right-sided (tricuspid or pulmonic) BPVT may cause pulmonary emboli; tricuspid BPVT can also rarely result in systemic embolic events via paradoxical embolization. (See <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Manifestations of valve dysfunction</strong> – Clinical manifestations of bioprosthetic valve dysfunction range from an incidentally detected change in prosthetic valve appearance or gradient on an echocardiogram performed for other reasons, a new murmur consistent with valve obstruction and/or regurgitation, symptoms and signs of heart failure caused by valve dysfunction (eg, dyspnea, fatigue, pulmonary crackles, cardiogenic shock), and, rarely, sudden death. (See <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial evaluation</strong> – The initial clinical evaluation includes transthoracic echocardiography (TTE) to assess bioprosthetic valve appearance, valve function (including mean transvalvular gradient and effective orifice area), and other potential sources of embolism. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Further evaluation</strong> – If BPVT, thromboembolism, or obstruction is suspected after the initial evaluation, additional evaluation involves advanced imaging (three-dimensional transesophageal echocardiography [3D TEE] and/or four-dimensional computed tomography [4D CT]), and exclusion of other causes of symptoms and signs (such as infective endocarditis). (See <a class="local">'Additional evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Obstruction </strong>– Prosthetic valve obstruction is identified by a mean transvalvular pressure gradient that is &gt;50 percent compared with baseline (or by a mean gradient ≥20 mmHg or an increase in mean gradient ≥10 mmHg for an aortic prosthesis [<a href="#rid20">20</a>]). Valve obstruction should be distinguished from other causes of left ventricular outflow tract obstruction or increased prosthetic transvalvular pressure gradients. (See <a class="local">'Diagnosis of obstruction'</a> above and <a class="local">'For valve obstruction'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Bioprosthetic valve thrombosis or pannus</strong> – The presence of increased cusp thickness with restricted leaflet mobility is suggestive of BPVT or pannus. BPVT is presumptively diagnosed when <strong>both</strong> increased cusp thickness (generally with no or mild calcification) and decreased cusp mobility are present on 3D TEE, and/or 4D CT with characteristics consistent with BPVT. Prosthetic valve endocarditis should be excluded. (See <a class="local">'Diagnosis of BPVT or pannus'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Thromboembolism</strong> – When a patient with a bioprosthetic valve experiences a presumed thromboembolic event (eg, stroke), a diagnosis of thromboembolism from the bioprosthetic valve is made after excluding other causes of stroke and embolic events. (See <a class="local">'Diagnosis of thromboembolism'</a> above and <a class="local">'For valve thromboembolism or thrombosis'</a> above and  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Whitlock RP, Sun JC, Fremes SE, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e576S.</a></li><li><a class="nounderline abstract_t">Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72.</a></li><li><a class="nounderline abstract_t">Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43:561.</a></li><li><a class="nounderline abstract_t">Hammermeister KE, Sethi GK, Henderson WG, et al. A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease. N Engl J Med 1993; 328:1289.</a></li><li><a class="nounderline abstract_t">Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.</a></li><li><a class="nounderline abstract_t">Dürrleman N, Pellerin M, Bouchard D, et al. Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute. J Thorac Cardiovasc Surg 2004; 127:1388.</a></li><li><a class="nounderline abstract_t">Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations. Heart 2007; 93:137.</a></li><li><a class="nounderline abstract_t">Sellers SL, Gulsin GS, Zaminski D, et al. Platelets: Implications in Aortic Valve Stenosis and Bioprosthetic Valve Dysfunction From Pathophysiology to Clinical Care. JACC Basic Transl Sci 2021; 6:1007.</a></li><li><a class="nounderline abstract_t">Cremer PC, Rodriguez LL, Griffin BP, et al. Early Bioprosthetic Valve Failure: Mechanistic Insights via Correlation between Echocardiographic and Operative Findings. J Am Soc Echocardiogr 2015; 28:1131.</a></li><li><a class="nounderline abstract_t">Egbe AC, Pislaru SV, Pellikka PA, et al. Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors. J Am Coll Cardiol 2015; 66:2285.</a></li><li><a class="nounderline abstract_t">Burke AP, Farb A, Sessums L, Virmani R. Causes of sudden cardiac death in patients with replacement valves: an autopsy study. J Heart Valve Dis 1994; 3:10.</a></li><li><a class="nounderline abstract_t">Karakoyun S, Gürsoy MO, Kalçık M, et al. A case series of prosthetic heart valve thrombosis-derived coronary embolism. Turk Kardiyol Dern Ars 2014; 42:467.</a></li><li><a class="nounderline abstract_t">Jaffe R, Shiran A, Rubinshtein R. Left main coronary artery occlusion due to thrombus embolization from a prosthetic mitral valve. JACC Cardiovasc Interv 2013; 6:e43.</a></li><li><a class="nounderline abstract_t">Jose J, Sulimov DS, El-Mawardy M, et al. Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. JACC Cardiovasc Interv 2017; 10:686.</a></li><li><a class="nounderline abstract_t">Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22:975.</a></li><li><a class="nounderline abstract_t">Lancellotti P, Pibarot P, Chambers J, et al. Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17:589.</a></li><li><a class="nounderline abstract_t">Makkar RR, Fontana G, Jilaihawi H, et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med 2015; 373:2015.</a></li><li><a class="nounderline abstract_t">Roslan AB, Naser JA, Nkomo VT, et al. Performance of Echocardiographic Algorithms for Assessment of High Aortic Bioprosthetic Valve Gradients. J Am Soc Echocardiogr 2022; 35:682.</a></li><li><a class="nounderline abstract_t">Luis SA, Blauwet LA, Samardhi H, et al. Usefulness of Mitral Valve Prosthetic or Bioprosthetic Time Velocity Index Ratio to Detect Prosthetic or Bioprosthetic Mitral Valve Dysfunction. Am J Cardiol 2017; 120:1373.</a></li><li><a class="nounderline abstract_t">VARC-3 WRITING COMMITTEE:, Généreux P, Piazza N, et al. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol 2021; 77:2717.</a></li><li><a class="nounderline abstract_t">Feuchtner GM, Stolzmann P, Dichtl W, et al. Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings. J Am Coll Cardiol 2009; 53:436.</a></li><li><a class="nounderline abstract_t">Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging 2013; 6:185.</a></li><li><a class="nounderline abstract_t">Zou H, Zhang Y, Tong J, Liu Z. Multidetector computed tomography for detecting left atrial/left atrial appendage thrombus: a meta-analysis. Intern Med J 2015; 45:1044.</a></li><li><a class="nounderline abstract_t">Ozkan M, Gürsoy OM, Astarcıoğlu MA, et al. Real-time three-dimensional transesophageal echocardiography in the assessment of mechanical prosthetic mitral valve ring thrombosis. Am J Cardiol 2013; 112:977.</a></li><li><a class="nounderline abstract_t">Hein M, Breitbart P, Minners J, et al. Performance of Computed Tomography Angiography (CTA) for the Diagnosis of Hypo-Attenuated Leaflet Thickening (HALT). J Clin Med 2022; 11.</a></li><li><a class="nounderline abstract_t">Puri R, Auffret V, Rodés-Cabau J. Bioprosthetic Valve Thrombosis. J Am Coll Cardiol 2017; 69:2193.</a></li><li><a class="nounderline abstract_t">Kagiyama N, Okura H, Nezuo S, et al. Two cases of acute bioprosthetic mitral valve thrombosis immediately after mitral valve replacement. Circulation 2014; 129:e328.</a></li><li><a class="nounderline abstract_t">Waterbury TM, Raphael CE, Padang R, et al. Not All Immobile Bioprosthetic Valve Cusps Are Thrombosed. JACC Cardiovasc Interv 2017; 10:e117.</a></li><li><a class="nounderline abstract_t">Naser JA, Crestanello JA, Nkomo VT, et al. Immobile Leaflets at Time of Bioprosthetic Valve Implantation: A Novel Risk Factor for Early Bioprosthetic Failure: A Novel Risk Factor for Early Bioprosthetic Failure. Heart Lung Circ 2022; 31:1166.</a></li><li><a class="nounderline abstract_t">Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015; 47:725.</a></li><li><a class="nounderline abstract_t">Egbe AC, Connolly HM, Pellikka PA, et al. Outcomes of Warfarin Therapy for Bioprosthetic Valve Thrombosis of Surgically Implanted Valves: A Prospective Study. JACC Cardiovasc Interv 2017; 10:379.</a></li><li><a class="nounderline abstract_t">Sethi P, Murtaza G, Rahman Z, et al. Valvular Hemolysis Masquerading as Prosthetic Valve Stenosis. Cureus 2017; 9:e1143.</a></li><li><a class="nounderline abstract_t">Barbetseas J, Pitsavos C, Aggeli C, et al. Comparison of frequency of left atrial thrombus in patients with mechanical prosthetic cardiac valves and stroke versus transient ischemic attacks. Am J Cardiol 1997; 80:526.</a></li></ol></div><div id="topicVersionRevision">Topic 113815 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315272" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33332150" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453165" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2021 ESC/EACTS Guidelines for the management of valvular heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469251" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11028464" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15115997" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35024507" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Platelets: Implications in Aortic Valve Stenosis and Bioprosthetic Valve Dysfunction From Pathophysiology to Clinical Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26275752" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early Bioprosthetic Valve Failure: Mechanistic Insights via Correlation between Echocardiographic and Operative Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26610876" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162204" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Causes of sudden cardiac death in patients with replacement valves: an autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25080955" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A case series of prosthetic heart valve thrombosis-derived coronary embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23866194" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Left main coronary artery occlusion due to thrombus embolization from a prosthetic mitral valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385406" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19733789" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143783" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436963" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35158051" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Performance of Echocardiographic Algorithms for Assessment of High Aortic Bioprosthetic Valve Gradients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28826894" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Usefulness of Mitral Valve Prosthetic or Bioprosthetic Time Velocity Index Ratio to Detect Prosthetic or Bioprosthetic Mitral Valve Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33888385" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179202" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406625" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26178177" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Multidetector computed tomography for detecting left atrial/left atrial appendage thrombus: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800549" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Real-time three-dimensional transesophageal echocardiography in the assessment of mechanical prosthetic mitral valve ring thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35407425" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Performance of Computed Tomography Angiography (CTA) for the Diagnosis of Hypo-Attenuated Leaflet Thickening (HALT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28449781" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bioprosthetic Valve Thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24515960" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Two cases of acute bioprosthetic mitral valve thrombosis immediately after mitral valve replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28579239" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Not All Immobile Bioprosthetic Valve Cusps Are Thrombosed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35339372" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Immobile Leaflets at Time of Bioprosthetic Valve Implantation: A Novel Risk Factor for Early Bioprosthetic Failure: A Novel Risk Factor for Early Bioprosthetic Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24829402" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28231905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outcomes of Warfarin Therapy for Bioprosthetic Valve Thrombosis of Surgically Implanted Valves: A Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28491484" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Valvular Hemolysis Masquerading as Prosthetic Valve Stenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285674" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of frequency of left atrial thrombus in patients with mechanical prosthetic cardiac valves and stroke versus transient ischemic attacks.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
